Table 1:
Baseline Characteristics of Patients
| Characteristic | All Patients (N=108) | Upfront Setting (N=72) | Relapsed/Refractory Setting (N=36) | Relapse After Upfront Decitabine Induction (N=8) |
|---|---|---|---|---|
| Male sex – no. (%) | 66 (61.1) | 49 (68.1) | 17 (47.2) | 5 (62.5) |
| Age at diagnosis – yr. | ||||
| Median | 71 | 74 | 67.5 | 76.5 |
| Range | 42–88 | 44–88 | 42–84 | 72–85 |
| Median WBC | 3.1 × 109/L | 3.0 × 109/L | 3.4 × 109/L | 2.1 × 109/L |
| Median hemoglobin | 9.2 g/dL | 9.0 g/dL | 9.5 g/dL | 9.1 g/dL |
| Median platelets | 49 × 109/L | 54 × 109/L | 40 × 109/L | 52 × 109/L |
| Cytogenetic risk groupa - no. (%) | ||||
| Favorable | 4 (3.7) | 3 (4.2) | 1 (2.8) | 0(0) |
| Intermediate | 51 (47.2) | 32 (44.4) | 19 (52.8) | 2 (25.0) |
| Unfavorable | 53 (49.1) | 37 (51.4) | 16 (44.4) | 6 (75.0) |
| Therapy-related AML - no. (%) | 26 (24.1) | 24 (33.3) | 2 (5.6) | 1 (12.5) |
| Prior MDS - no. (%) | 33 (30.6) | 25 (34.7) | 4 (50.0) | |
| Total number of comorbidities | ||||
| Median | 3 | 3 | 2 | 3 |
| Range | 0–6 | 0–6 | 0–5 | 0–5 |
| Charlson comorbidity index scoreb | ||||
| Median | 1 | 1 | 1 | 1 |
| Range | 0–10 | 0–10 | 0–6 | 0–3 |
| HCT-CI comorbidity scorec | ||||
| Median | 3 | 3 | 3 | 2 |
| Range | 0–9 | 0–9 | 0–8 | 0–5 |
| Stem cell transplant - no. (%) | 7 (6.5) | 3 (4.2) | 4 (11.1) | 0 (0) |
| Total 10-day cycles of decitabine | ||||
| Median | - | 2 | 2 | 2 |
| Range | - | 1–8 | 1–7 | 1–4 |
| Total 5-day cycles of maintenance decitabine after 10-day induction | ||||
| Median | - | 6 | 0 | 0 |
| Range | - | 0–66 | 0–20 | 0–4 |
a
The cytogenetic risk groups were stratified according to ELN criteria. Intermediate-I and intermediate-II groups were combined into a single intermediate group.
b
The Charlson comorbidity index score is a weighted index that predicts the risk of death within one year of hospitalization.21
c
The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed to identify comorbidities associated with stem cell transplantation and to assess risk prior to allogeneic transplant.20